Pediatric Dermatology Research Alliance - PeDRA’s Post

🎙️ New Conversations with Collaborators: PeDRA and Sanofi 🎙️ We are thrilled to share the second episode in the PeDRA Conversations with Collaborators podcast series! In this interview, PeDRA and Sanofi discuss how they are working together to advance pediatric dermatology research, combining their expertise and resources to drive innovation and improve care for children affected by skin diseases. Through this collaboration, they aim to support groundbreaking studies, foster new treatments, and provide greater opportunities for researchers to address unmet needs in pediatric dermatology. This interview includes information on a therapy currently under clinical investigation. Thus, no conclusions on its efficacy and safety can be drawn. 🎧 Listen on PeDRA Pearls or click here 👉 https://lnkd.in/e85Bm8_B #PeDRA #pedraresearch #pedsderm #dermatologyresearch #dermpodcast

NEW TREATMENTS = NEW RESEARCH = NEW THINKING ABOUT DISEASE STATES. FINALLY SEBORRHEIC DERMATITIS IS GETTING SOME LONG-DESERVED ATTENTION AS A STAND ALONE DISEASE STATE. SOMEHOW WE ALL KNEW IT. NOW WE HAVE SOME DATA TO BETTER EXPLAIN IT. The "journey" of seborrheic dermatitis (SD) is showing signs of coming around full circle. The puzzle was left unfinished for about 2 decades after research implicating Malassezia spp as the "root cause" of SD did not fully make sense as an explanation. Just like a good unfinished mystery story come to light over time, new pieces of the puzzle emerge that help explain more clearly the basis of what we see and treat as clinicians. Dr. Chovatiya takes a shot at discussing where our understanding of SD is right now, and does a great job of explaining how the pieces of the puzzle are coming together. In my mind, having been close to it for so long, it is often good to step back and take a fresh look at something we have seen in front of us for a long time. It took just a few pieces of new fundamental data and analysis to open our eyes beyond being stuck in the same recycled dogma. SD has been given a makeover which has been long overdue. More to come from Dr. Raj C I am sure, and many of the rest of us who are stimulated by the desire to better understand and manage chronic inflammatory skin diseases. See the repost below.

Journal of Dermatology for NPs & PAs co-founder and editor Douglas DiRuggiero, DMSc, MHS, PA-C, talks to Raj Chovatiya, MD, PhD, MSCI, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, IL, about how and why to encourage non-segmental #vitiligo patients to stick with daily application of ruxolitinib cream 1.5% (Opzelura, Incyte). They also discuss how this cream repigments multiple body parts in vitiligo and share tips on the best ways to address patient safety concerns. https://lnkd.in/dqhr7RW9

Diving into dermatology research with Dr. Robert Bissonnette and Dr. Kim Papp! 💡 📊 From Innovaderm and Probity Medical Research Inc., they tackled the key challenges in conducting vitiligo studies, the intricacies of early phase studies, and shared insights into alopecia areata (AA) studies 🔬 “[...] a shift in regulatory preferences has emerged: some authorities now advocate for single ascending dose (SAD) studies exclusively in healthy volunteers, while recommending that multiple ascending dose (MAD) studies be conducted directly in patients.” Robert Bissonnette, Innovaderm Research #dermatologyCRO #clinicalresearch #partnership #dermatalogyexperts __ Plongez dans la recherche dermatologique avec Dr Bissonnette et Dr Papp! 💡 📊 Suivez le lien pour accéder à l’entrevue complète (en anglais seulement)

Through interviews with experts in oncology, orphan diseases, dermatology, and more, we've gained invaluable perspectives to drive better outcomes. Our Re-thinking Market Access study uncovers current challenges, trends, and strategic solutions for the Market Access function, offering a systematic approach to assess performance and develop effective solutions. If you want an in-depth discussion on the gathered insights or a conversation on the implications for your company, please get in touch with our CapSys Group experts, David Bristol and Kenneth Weissmahr. https://lnkd.in/egfFy5S2 #MarketAccess #Medical #LifeSciences #StrategyConsulting #MedicalAffairs #Business #BusinessStrategy

Dermatology is a number of therapeutic categories that used to be considered moribund - genericized, low growth and devoid of innovation. Years before that, the same was true of vaccines and oncology, and big pharma (save for a few exceptions) either divested or kept out of them. Now, all three have been revolutionized by new biological science. This review by Alex Yule succinctly summarizes the state of play in the derma field. https://lnkd.in/dw5VS2m4

Happy New Year to everyone! This post is a kind reminder that the SPIN page is about to be closed. More details below👇🏼

If you are interested in dermatology and how basic research is translated into a clinical environment do not hesitate to subscribe to the "International Doctoral Summer School in Dermatology" organized by University of Granada (Spain) in September. 🔬 ➡ 🏥 It doesn't matter if you are a student, a researcher or a clinician, this is a multidisciplinary course where you will learn how several fields of science work together to discover and find solutions to some of the most relevant issues in the field of clinical dermatology. ℹ 👇 https://lnkd.in/daETQRvP

What a great conversation with Julia Regan, MBA! It was such a pleasure talking to you and learning all about RxLightening! Check out the first episode of 2024!! #thatsdermgood #womeninbusiness #dermatology #healthcareadvocate #patientcare #bceducators

🧬 𝐖𝐡𝐲 𝐝𝐨𝐞𝐬 #𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐩𝐥𝐚𝐲 𝐚𝐧 𝐞𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐫𝐨𝐥𝐞 𝐢𝐧 𝐝𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲? In recent decades, the development of novel and highly specific therapeutics has increased a lot in dermatology, especially for conditions such as melanoma, psoriasis, and eczema. However, diagnostic techniques have not advanced at the same pace, preventing highly specific therapeutics from reaching their full potential. This large gap between diagnostics and therapeutics is being bridged by DNA- and RNA-based molecular diagnostics. Dermagnostix started on building this bridge with #PsorX – the worldwide first molecular test for the differential diagnosis of psoriasis and eczema! You want to join our journey of #MovingDiagnosticFrontiers in dermatology? Subscribe to our #newsletter: https://lnkd.in/eRCXcTVB #BeyondTheSurface #Psoriasis #Eczema